Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern cooperative oncology group protocol E4402

Journal of Clinical Oncology

Volumn 32, Issue 28, 2014, Pages 3096-3102

  Kahl, Brad S ^a   Hong, Fangxin ^a   Williams, Michael E ^a   Gascoyne, Randy D ^a   Wagner, Lynne I ^a   Krauss, John C ^a   Habermann, Thomas M ^a   Swinnen, Lode J ^a   Schuster, Stephen J ^a   Peterson, Christopher G ^a   Sborov, Mark D ^a   Martin, S Eric ^a   Weiss, Matthias ^a   Ehmann, W Christopher ^a   Horning, Sandra J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BRAIN DISEASE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DRUG TREATMENT FAILURE; FAINTNESS; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; INTERMETHOD COMPARISON; LARYNX PAIN; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; THROMBOCYTOPENIA; TIME TO TREATMENT; TUMOR VOLUME; VERY ELDERLY; WEAKNESS; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECTS; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPENIA; PROGNOSIS; QUALITY OF LIFE; RETREATMENT; RITUXIMAB; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84907883655     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.5853     Document Type: Article

References (25)

1. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
2. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single firstline therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 97:101-106, 2001
3. Witzig TE, Vukov AM, Habermann TM, et al: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23:1103-1108, 2005
4. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in the United States: First report of the National LymphoCare Study. J Clin Oncol 27:1202-1208, 2009
5. Hainsworth JD, Litchy S, Burris HA 3rd, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002
6. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule. Blood 103:4416-4423, 2004
7. Martinelli G, Schmitz SF, Utiger U, et al: Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 28:4480-4484, 2010
8. Davis TA, Grillo-López AJ, White CA, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143, 2000
9. Hainsworth JD, Litchy S, Shaffer DW, et al: Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma- A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:1088-1095, 2005
10. Brice P, Bastion Y, Lepage E, et al: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires- Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15:1110-1117, 1997
11. Young RC, Longo DL, Glatstein E, et al: The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment. Semin Hematol 25:11-16, 1988 (suppl 2)
12. Ardeshna KM, Smith P, Norton A, et al: Longterm effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet 362:516-522, 2003
13. Colombat P, Brousse N, Salles G, et al: Rituximab induction immunotherapy for first-line lowtumor- burden follicular lymphoma: Survival analyses with 7-year follow-up. Ann Oncol 23:2380-2385, 2012
14. Webster K, Cella D: Quality of life in patients with low-grade non-Hodgkin's lymphoma. Oncology (Williston Park) 12:697-714, 1998; discussion 714, 717, 721
15. Stabler B, Berkowitz L, Schell M, et al: Quality of life in patients treated with rituximab as a single agent. J Clin Oncol 20:279a, 2002 (suppl; abstr 2693)
16. Witzens-Harig M, Reiz M, Heiss C, et al: Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: Results of a prospective randomized controlled trial. Ann Hematol 88:51-57, 2009
17. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI-sponsored international working group. J Clin Oncol 17:1244, 1999
18. Berinstein NL, Grillo-López AJ, White CA, et al: Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9:995-1001, 1998
19. Gordan LN, Grow WB, Pusateri A, et al: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23:1096-1102, 2005
20. Hochster H, Weller E, Gascoyne RD, et al: Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study. J Clin Oncol 27:1607-1614, 2009
21. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
22. Centers for Medicare and Medicaid Services: Medicare Part B Drug Average Sales Price. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html?redirect-/McrPartBDrugAvgSalesPrice/
23. Vidal L, Gafter-Gvili A, Leibovici L, et al: Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and metaanalysis of randomized trials. J Natl Cancer Inst 101:248-255, 2009
24. Ardeshna KM, Qian W, Smith P, et al: Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol 15:424-435, 2014
25. Wagner LI, Zhao F, Williams ME, et al: Quality of life results from Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for indolent non-Hodgkin's lymphoma. Blood 120, 2012 (abstr 235)